Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30592218 | 1.00 | GAA (0.49) | GAAALDH1A1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL1085394 | 0.87 | SMN1; SMN2 (0.50) | GAAALDH1A1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL8840383 | 0.87 | POLB (0.57) | GAAALDH1A1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL24772939 | 0.86 | GAA (0.53) | GAAALDH1A1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL21120427 | 0.85 | GLP1R (0.49) | GAAALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL12380495 | 0.84 | KDM4E (0.44) | GAAALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL17221704 | 0.84 | POLB (0.53) | GAAALDH1A1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL17076373 | 0.84 | NR1H2 (0.47) | GAAALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL15760943 | 0.84 | GAA (0.47) | GAAALDH1A1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL25136864 | 0.84 | KDM4E (0.51) | GAAALDH1A1SMN1; SMN2KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025090480-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-01 | — | — | WO | disclosed |
| CN-119855815-A | KRAS mutant protein inhibitor, and preparation method and application thereof | 甘李药业股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| WO-2025064848-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIDINE KRAS INHIBITORS | Treeline Biosciences, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| CN-119156381-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-4466260-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024181803-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | 보로노이 주식회사 | 2024-09-06 | — | — | WO | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-7115608-B2 | Pyridinone and pyridinethione derivatives having HIV inhibiting properties | CENTRE NATIONAL DE LA RECHERCHE SCHENTIFIQUE (FR) | 2006-10-03 | — | — | US | disclosed |
| EP-1318995-B1 | PYRIDINONE AND PYRIDINETHIONE DERIVATIVES HAVING HIV INHIBITING PROPERTIES | CENTRE NAT RECH SCIENT (FR) | 2006-03-08 | — | — | EP | disclosed |
| EP-1565452-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINES AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040229847-A1 | Pyridinone and pyridinethione derivatives having hiv inhibiting properties | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-11-18 | — | — | US | disclosed |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | NEUROGEN CORPORATION | 2004-08-12 | — | — | US | disclosed |
| WO-2004043925-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINED AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-1318995-A2 | PYRIDINONE AND PYRIDINETHIONE DERIVATIVES HAVING HIV INHIBITING PROPERTIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024650-A2 | PYRIDINONE AND PYRIDINETHIONE DERIVATIVES HAVING HIV INHIBITING PROPERTIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | GAA 2474/4885ALDH1A1 4061/4885SMN1; SMN2 782/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | GAA 2454/4885ALDH1A1 4050/4885SMN1; SMN2 787/4885 |
| US-20040229847-A1 | Pyridinone and pyridinethione derivatives having hiv inhibiting properties | CYP2B6, CYP2S1, CYP2D6 | GAA 4710/4885ALDH1A1 619/4885SMN1; SMN2 4627/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | GAA 2474/4885ALDH1A1 4061/4885SMN1; SMN2 782/4885 |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | C3AR1, C5AR1, C5AR2 | GAA 4839/4885ALDH1A1 1444/4885SMN1; SMN2 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.